Claims
- 1. A compound of formula (I):
- 2. A compound or pharmacologically acceptable salt or ester thereof according to claim 1, wherein the group of formula: R1—C(═X1)— is a carbamoyl group, a (C1-C4 alkyl)carbamoyl group, a di(C1-C4 alkyl)carbamoyl group, a thiocarbamoyl group, a (C1-C4 alkyl)thiocarbamoyl group or a di(C1-C4 alkyl)thiocarbamoyl group.
- 3. A compound or pharmacologically acceptable salt or ester thereof according to claim 1, wherein the group of formula: R1—C(═X1)— is a (C1-C4 alkyl)carbamoyl group, a di(C1-C4 alkyl)carbamoyl group, a (C1-C4 alkyl)thiocarbamoyl group or a di(C1-C4 alkyl)thiocarbamoyl group.
- 4. A compound or pharmacologically acceptable salt or ester thereof according to claim 1, wherein the group of formula: R1—C(═X1)— is a (C1-C4 alkyl)carbamoyl group or a di(C1-C4 alkyl)carbamoyl group.
- 5. A compound or pharmacologically acceptable salt or ester thereof according to claim 1, wherein the group of formula: R1—C(═X1)— is a di(C1-C4 alkyl)carbamoyl group.
- 6. A compound or pharmacologically acceptable salt or ester thereof according to claim 1, wherein the group of formula: R1—C(═X1)— is a dimethylcarbamoyl group or an ethylmethylcarbamoyl group.
- 7. A compound or pharmacologically acceptable salt or ester thereof according to claim 1, wherein the group of formula: R1—C(═X1)— is a dimethylcarbamoyl group,
- 8. A compound or pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 7, wherein R3 is a C1-C6 alkyl group.
- 9. A compound or pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 7, wherein R3 is a methyl group or an ethyl group.
- 10. A compound or pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 7, wherein R3 is a methyl group.
- 11. A compound or pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 10, wherein R2 is a hydrogen atom or a C1-C6 alkyl group.
- 12. A compound or pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 10, wherein R2 is a hydrogen atom, a methyl group or an ethyl group.
- 13. A compound or pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 10, wherein R2 is a hydrogen atom or a methyl group.
- 14. A compound or pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 10, wherein Ra, together with R2, is a C1-C3 alkylene group which may contain a double bond.
- 15 A compound or pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 10, wherein Ra, together with R2, is a C2-C3 alkylene group which may contain a double bond.
- 16. A compound or pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 10, wherein Ra, together with R2, is a C3 alkylene group which contains a double bond.
- 17. A compound or pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 13, wherein Ra is a hydrogen atom or a methyl group.
- 18. A compound or pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 13, wherein Ra is a hydrogen atom.
- 19. A compound or pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 18, wherein Arom is a phenyl group, a phenyl group substituted at from 1 to 3 positions by substituent(s) which may be the same or different selected from the substituent group α, a pyridyl group, or a pyridyl group substituted at one position by a substituent selected from the substituent group α;
- 20. A compound or pharmacologically acceptable salt or ester thereof according to any one of claims lto 18, wherein Arom is a phenyl group or a phenyl group substituted at from 1 to 3 positions by substituent(s) which may be the same or different selected from the substituent group α;
- 21. A compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 18, wherein Arom is a phenyl group substituted at one or two positions by substituent(s) which may be the same or different selected from the substituent group α1, or a phenyl group substituted at three positions by halogen atoms;
- 22. A compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 18, wherein Arom is a phenyl group substituted at one or two positions by substituent(s) which may be the same or different selected from the substituent group α2, or a phenyl group substituted at three positions by fluorine atoms or chlorine atoms;
- 23. A compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 18, wherein Arom is a phenyl group substituted at one or two positions by substituent(s) which may be the same or different selected from the substituent group α3, or a phenyl group substituted at three positions by fluorine atoms;
- 24. A compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 18, wherein Arom is a phenyl group substituted at one or two positions by substituent(s) which may be the same or different selected from the substituent group α4, or a phenyl group substituted at three positions by fluorine atoms;
- 25. A compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 18, wherein Arom is a phenyl group substituted at one position by a fluorine atom, a chlorine atom or a nitro group, or a phenyl group substituted at two positions by fluorine atoms.
- 26. A compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 18, wherein Arom is a 4-fluorophenyl group, a 4-chlorophehyl group, a 4-nitrophenyl group or a 3,4-difluorophenyl group.
- 27. A compound or pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 26, wherein A is a C1-C4 alkylene group.
- 28. A compound or pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 26, wherein A is a methylene group or an ethylene group.
- 29. A compound or pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 26, wherein A is an ethylene group.
- 30. A compound or pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 29, wherein E is an oxygen atom or a single bond.
- 31. A compound or pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 29, wherein E is an oxygen atom.
- 32. A compound or pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 31, wherein X2 is an oxygen atom.
- 33. A compound or pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 32, wherein the group of formula: R1—C(═X1) —X2— is attached at the para-position.
- 34. A compound or pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 32, wherein R1 is an amino group, a (C1-C6 alkyl)amino group or a di(C1-C6 alkyl)amino group.
- 35. A compound or pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 32, wherein R1 is an amino group, a (C1-C4 alkyl)amino group or a di(C1-C4 alkyl)amino group.
- 36. A compound or pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 32, wherein R1 is a (C1-C4 alkyl)amino group or a di(C1-C4 alkyl)amino group.
- 37. A compound or pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 32, wherein X1 is an oxygen atom.
- 38. The compound or pharmacologically acceptable salt or ester thereof according to claim 1, wherein the compound is 4-[3-(4-nitrophenoxy)-1-methylaminopropyl]phenyl dimethcarbamate.
- 39. A compound of the formula (I):
- 40. A pharmaceutical composition containing a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 39 in combination with a pharmaceutically acceptable carrier.
- 41. A method for inhibiting acetylcholinesterase and selective serotonin reuptake in a human comprising administering to said human a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 39.
- 42. A method for treating or preventing Alzheimer's disease, depression, Huntington's chorea, Pick's disease, tardive dyskinesia, compulsive disorders or panic disorders in a human comprising administering to said human a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 39.
- 43. The method according to claim 42, wherein the method is for treating or preventing Alzheimer's disease.
- 44. A method for inhibiting acetylcholinesterase and selective serotonin reuptake in a mammal comprising administering to a mammal a pharmaceutically effective amount of a compound or a pharmaceutically acceptable salt or ester thereof according to claim 1.
- 45. A method for treating or preventing Alzheimer's disease, depression, Huntington's chorea, Pick's disease, tardive dyskinesia, compulsive disorders or panic disorders in a mammal comprising administering to a mammal a pharmaceutically effective amount of a compound or a pharmacologically acceptable salt or ester thereof according to claim 1.
Priority Claims (2)
Number |
Date |
Country |
Kind |
2001-18386 |
Jan 2001 |
JP |
|
2001-305182 |
Oct 2001 |
JP |
|
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application is a continuation-in-part application of International Application PCT/JPO2/00400 filed Jan. 22, 2002, the entire contents of which are hereby incorporated by reference herein.
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
PCT/JP02/00400 |
Jan 2002 |
US |
Child |
10629108 |
Jul 2003 |
US |